BDBM620655 US20230303513, Example 96::US20230303513, Example 97

SMILES COc1cc(F)c([C@@H]2CN(C(=O)[C@H]2NC(=O)N[C@H]2CC[C@@H](CC2)C(F)F)c2nccc(N3C[C@@H]4C[C@H]3CN4C)c2C(F)(F)F)c(F)c1

InChI Key InChIKey=AAHHGEULGBIDPR-UHFFFAOYSA-N

Data  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 620655   

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620655(US20230303513, Example 97 | US20230303513, Example...)
Affinity DataEC50:  0.400nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620655(US20230303513, Example 97 | US20230303513, Example...)
Affinity DataEC50:  4.60nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620655(US20230303513, Example 97 | US20230303513, Example...)
Affinity DataEC50:  1.40E+3nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620655(US20230303513, Example 97 | US20230303513, Example...)
Affinity DataEC50:  3.40E+3nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent